Teaming up with researchers in Copenhagen, they showed that a PAM defect does not alter the GLP-1 receptors ability to bind GLP-1, nor how the hormone signals through the receptor
If youre considering weight loss medication, you likely have questions about what results you can expect and how they fit into your overall body transformation plan
The key finding is that GLP-1 can be detected in synovial fluid, Kragstrup said
Semaglutide may be appropriate for some non-diabetic patients who meet weight-management criteria, but it is not right for everyone
Learning to eat to the point of satisfaction rather than fullness is an important behavioral adjustment
In the Phase 2 obesity trial published in NEJM in 2023, retatrutide at the 12 mg weekly dose produced a mean placebo-adjusted body weight reduction of 22.1 percentage points (22.1% (24.2% arm) mean absolute reduction on the retatrutide arm) at 48 weeks (Jastreboff et al., NEJM, 2023)